AMAL Therapeutics finalises €29 million (CHF 33.2 million) Series B round

/in /by

Geneva, Switzerland – 12 September 2018 – AMAL Therapeutics (AMAL), the Swiss biotech developing novel, peptide-based therapeutic cancer vaccines, today announces that it has completed the second closing of its Series B financing round. The second and final tranche of €21.2 million (CHF 24.2 million) brings the total round to just over €29 million (CHF […]

Read more

Amal Therapeutics featured in September edition of BioPharma Dealmaker (Springer-Nature)

/in /by

Geneva, Switzerland – 19 September 2018 – We are pleased to announce that AMAL Therapeutics is featured in the September edition of BioPharma Dealmakers (Nature Research), outlining the promise of protein-based therapeutics cancer vaccine in oncology.   View PDF

Read more

ESMO Geneva 13-16 Dec 2018

/in , /by

ESMO Immuno Oncology – Geneva 2018 13-16 December / Geneva / Switzerland Amal Therapeutics Team attending

Read more

4th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference 30 sept 2018

/in , /by

4th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference 30 September – 3 October 2018 / New York, NY / USA Jean-François Mayol attending

Read more

IPO Day 13 June 2018

/in , /by

IPO Day Lausanne 2018 13 June / Lausanne / Switzerland Madiha Derouazi attending

Read more